Over a median of 3.4 years, the risk of major kidney disease events was 24% lower on semaglutide. It was stopped early because the result was clear, and published in the New England Journal of Medicine in 2024.1
How the trial was run
Participants had type 2 diabetes and chronic kidney disease defined by two lab measures: eGFR, an estimate of how well the kidneys filter blood, and the amount of albumin, a protein, in the urine. People qualified with an eGFR of 50 to 75 and a urine albumin-to-creatinine ratio above 300, or an eGFR of 25 to under 50 and a ratio above 100; in both cases the ratio had to be below 5,000. The Ozempic label adds that everyone had an HbA1c of 10% or less and was already on standard kidney protection, including the highest tolerated dose of an ACE inhibitor or an angiotensin receptor blocker unless they could not take one. Inherited and autoimmune kidney diseases were excluded. The average participant was 67 years old, and 70% were men.2 They were assigned in equal numbers, 1,767 to semaglutide and 1,766 to placebo.1
The main outcome combined kidney failure, meaning dialysis, a transplant or an eGFR below 15; a drop in eGFR of at least 50% from the start; and death from kidney or cardiovascular causes. Further outcomes were tested in a fixed order, so that each counted only if the one before it was met. An interim analysis led to a recommendation to stop the trial early, after a median follow-up of 3.4 years.1
What it found
- Major kidney disease events: 331 first events on semaglutide against 410 on placebo, a hazard ratio of 0.76, or 24% lower risk.
- The kidney-only part of that outcome: a hazard ratio of 0.79.
- Cardiovascular death: a hazard ratio of 0.71.
- Major cardiovascular events: 18% lower risk, a hazard ratio of 0.82.
- Death from any cause: 20% lower risk.
- The yearly fall in eGFR was slower on semaglutide, by 1.16 milliliters per minute per 1.73 square meters of body surface.
Perkovic et al., 2024.1
On the basis of FLOW, the Ozempic label added a third use: reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.2
Side effects
Serious adverse events were reported in a lower share of people on semaglutide than on placebo.1 The Ozempic label still warns about acute kidney injury from fluid loss: nausea, vomiting and diarrhea can dehydrate, and the label asks for kidney function to be watched in people with those reactions.2 For someone with kidney disease, staying hydrated through stomach side effects matters more than for most. Our page on diarrhea on a GLP-1 covers what to drink.
Why it matters
Unlike the earlier heart trials of GLP-1 medicines, FLOW was designed around kidney outcomes. Its result lowered kidney events, heart events and deaths from any cause together, in a trial stopped early because the answer was already clear.1 That consistency across outcomes is what turned it into a new use on the Ozempic label.
Limits
FLOW enrolled only people with type 2 diabetes, so it does not show whether semaglutide protects the kidneys of people without diabetes. It used 1.0 mg, not the higher Ozempic or Wegovy doses. It was funded by Novo Nordisk, the maker of semaglutide.1
Sources
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391:109-121. Funded by Novo Nordisk; NCT03819153. doi:10.1056/NEJMoa2403347
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 5.6 and 14.3. accessdata.fda.gov
Related analyses
Ozempic side effects: how common each one is by dose, and when they ease
Ozempic dosing schedule: 0.25 mg to 2 mg, week by week, with your own dates
Ozempic vs Mounjaro: what the head-to-head trial and the two labels show
Diarrhea on a GLP-1: how common, how long, what to drink and when to call
Log your doses with lab results such as eGFR and see them over time.
Open Dose Insider